CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today a poster presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024 Meeting, held May 5-8 in Atlanta, GA. The presented research is a targeted literature review of the clinical, humanistic, and economic burden of Alzheimer’s Disease (AD).
By 2060, AD is expected to affect 13.8 million individuals in the US, driven by a 47% increase in the US population aged 65 and older by 2050. This surge underscores the pressing need for improved understanding and management of this debilitating neurological disease, given the current limitations in treatment options. A targeted literature review was conducted to gain insights into the clinical, humanistic, and economic burden of mild-to-moderate AD, including mild cognitive impairment (MCI). This comprehensive analysis includes patient demographics, prognostic factors, risks contributing to disease severity and progression, as well as pivotal factors impacting both patient and caregiver quality of life and healthcare resource utilization.
“In light of the continued rise in projected Alzheimer's cases, this comprehensive review underscores the profound impact of mild-to-moderate AD and MCI on patients, caregivers, and healthcare systems,” said Ralph Kern, MD, MHSc, Chief Medical Officer, Cognito Therapeutics. “This analysis reveals a number of factors influencing disease progression, quality of life, and healthcare resource utilization. The results highlight the need to better address and help AD patients proactively by developing novel disease-modifying therapies to alleviate the massive burden on the healthcare system.”
Details of the poster presentation:
Title: A Targeted Literature Review of Clinical, Humanistic, and Economic Burden of Alzheimer’s Disease in the United States
Presenter: Lily Lee, Ph.D., VP, Medical Affairs, Cognito Therapeutics
Poster Session: Poster Session 1
Poster Code: EPH39
Presentation Date/Time: Monday, May 6, 2024, 10:30 AM-1:30PM
Discussion Period: 12:30PM-1:30PM
About Cognito Therapeutics
Cognito Therapeutics is a late clinical-stage neurotechnology company dedicated to the development of transformative disease-modifying therapies for neurodegenerative diseases. Cognito’s proprietary approach targets dysregulated network activity in the brain and has shown meaningful outcomes in Alzheimer’s patients. Cognito’s lead product, Spectris, employs a proprietary non-invasive method designed to evoke increased gamma frequency brain activity using auditory and visual neuromodulation to slow the rate of brain atrophy and loss of brain function. Cognito’s mission is to develop a new class of technology-based therapeutic interventions to transform the lives of patients with neurodegenerative diseases. Cognito is headquartered in Cambridge, MA. For more information, visit www.cognitotx.com.
